3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Ovarian Neoplasms
10
Endometrial Neoplasms
6
Fallopian Tube Neoplasms
4
Breast Neoplasms
4
Neoplasms
3
Carcinoma, Ovarian Epithelial
3
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Paget's Disease, Mammary
1
Neoplasms by Site
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
Head and Neck Neoplasms
1
Endometrial Hyperplasia
1
Carcinoma, Intraductal, Noninfiltrating
1
Breast Diseases
1
Breast Carcinoma In Situ
1
Advanced, Persistent, or Recurrent Endometrial Cancer
1
Interventions
Fulvestrant
2
serabelisib
1
sapanisertib
1
ribociclib
1
palbociclib
1
olaparib
1
niraparib
1
inavolisib
1
exemestane
1
capivasertib
1
abemaciclib
1
Tamoxifen
1
STX-478
1
Paclitaxel
1
Metformin
1
Letrozole
1
Irinotecan
1
Imlunestrant
1
Gemcitabine
1
CYH33
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Tamoxifen
×
Gynecologic
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled